CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.

Phase 1/2 Unknown 30 enrolled Sant Pau Research Institute Instituto de Salud Carlos III · collab Josep Carreras Leukaemia Research Institute · collab

NaSingle-groupOpen-labelTreatment

Summary

HSP-CAR30 is a cell suspension of genetically modified T-cells to express a second generation (4-1BBz) chimeric antigen receptor (CAR) directed against CD30. This is a phase I/IIa, interventional, single arm, open label, treatment study to evaluate the safety, tolerability and efficacy of HSP-CAR30 in patients with relapsed/refractory Hodgkin lymphoma and relapsed/refractory T-cell lymphoma expressing CD30.

Timeline

Start: 2020-09-29
Primary completion: 2023-12-30
Completion: 2023-12-30

Publications

Caballero AC, Ujaldon-Miro C, Pujol-Fernandez P, Montserrat-Torres R, Guardiola-Perello M, Escudero-Lopez E, Garcia-Cadenas I, Esquirol A, Martino R, Jara-Bustamante P, Ezquerra P, Soria JM, Iranzo E, Moreno-Martinez ME, Riba M, Sierra J, Alvarez-Fernandez C, Escriba-Garcia L, Briones J. HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma. Blood. 2025 Apr 17;145(16):1788-1801. doi: 10.1182/blood.2024026758.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSP-CAR30	Cell therapy	3e+06 cells/kg	—
Subject	HSP-CAR30	Cell therapy	1e+07 cells/kg	—

CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.

Summary

Timeline

Publications

Drugs

Indications